Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
|
|
|
247 !
|
Mon, 7/30/2018,
2:00 PM -
3:50 PM
|
CC-West 205
|
|
Clinical Trial Design- 2 — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Weining Robieson
|
|
2:05 PM
|
Extension of Bayesian Logistic Regression Model (BLRM) for Dose Timing Selection in Oncology Phase I Combination Studies
Yiyun Zhang, Novartis; Nigel Yateman, Novartis; Fang Xiang, Novartis; Lan Yi, Novartis; Kapildeb Sen, Novartis; Beat Neuenschwander, Novartis
|
|
2:20 PM
|
Considering Delayed Treatment Effect in Trial Designs with Survival Endpoints
Kaushal Mishra, Novartis Oncology Pharmaceuticals; Kalyanee Viraswami Appanna, Novartis Pharmaceuticals
|
|
2:35 PM
|
Application of Bayesian Analyzes to Doubly-Randomized Delayed-Start, Matched Control Designs to Demonstrate Disease Modification
Ibrahim Turkoz, Janssen Research and Development, LLC; Marcus Sobel, Temple Universisity; Larry Alphs, Janssen Scientific Affairs, LLC
|
|
2:50 PM
|
A Strategy for the Design and Analysis of Bridging Studies
Eric Holmgren, Beigene
|
|
3:05 PM
|
Bayesian Isotonic Optimal Dose Design for Phase I/II Clinical Trials with Ordered Groups
Xiaoqiang Xue
|
|
3:20 PM
|
Evaluation of Regional Efficacy Equivalence in Developing Biosimilars
Ryuji Uozumi, Kyoto University Graduate School of Medicine; Shinjo Yada, A2 Healthcare Corporation
|
|
3:35 PM
|
Statistical Methodologies to Detect Ineffective Regional Treatment Effect in a Multiregional Trial
Hsiao-Hui Tsou, National Health Research Institutes; Yu-Chieh Cheng, National Health Research Institutes; Chin-Fu Hsiao, National Health Research Institutes
|
